2024-01-03 06:09:00
Bridge Biotherapeutics (CEO Jeong-gyu Lee) is holding a business development (BD) event including CEO Jeong-gyu Lee in line with the ‘2024 JP Morgan Healthcare Conference (JPMHC)’ held in San Francisco, USA from the 8th (local time) to the 11th. It was announced on the 3rd that a business trip team consisting of professional executives would be dispatched to the site.
The company plans to meet with global pharmaceutical and bio companies during the JPMHC period to explore technology transfer opportunities for key research and development (R&D) tasks and seek partnerships for new anti-cancer combination therapies. In particular, following the multi-national clinical trial of ‘BBT-877 (development code name)’, a candidate for the treatment of idiopathic pulmonary fibrosis, began in earnest and a number of confidentiality agreements (CDA) were signed with top global pharmaceutical companies, 1: 1 Face-to-face meetings will be held in the United States.
In addition, as research on the correlation between PD-1 immune checkpoint inhibitor response rate and autotaxin increases, new opportunities for collaboration with global pharmaceutical companies are being sought to develop a combination therapy of BBT-877, which is being developed as an autotaxin inhibitor, and immunotherapy. do. In addition to BBT-877, discussions on the transfer of global and regional rights to ‘BBT-207’, a non-small cell lung cancer targeted treatment candidate currently undergoing active clinical trials for patients, are also expected to begin through this meeting.
In addition, a number of meetings are scheduled to be held for the purpose of attracting investment to expand the size of the Boston Discovery Center (BDC), which began in Boston, USA in 2021, and to establish an independent operating system. Attracting investment for the independent branding of the US subsidiary will be led by Christopher Kim, the head of the US branch.
Lee Jeong-gyu, CEO of Bridge Biotherapeutics, said, “We plan to work tirelessly to take a strong step forward at JPMHC, which will be a very meaningful year due to the business development performance of the company’s core tasks and the launch of the independent operating system of the U.S. corporation.” “As discussions are scheduled with various global pharmaceutical and bio companies, we will strive to showcase our results as soon as possible,” he said.
Meanwhile, the company has designated lung cancer and idiopathic pulmonary fibrosis as major strategic disease areas since 2021 and is upgrading the related R&D pipeline. In addition, in recognition of the innovativeness of R&D projects and related corporate capabilities, the company was selected as an ‘Innovative Pharmaceutical Company Certified by the Ministry of Health and Welfare’ in 2023.
1704267343
#Bridge #Bio #Exploring #global #business #development #cooperation #JPMHC
